Rick Doblin

FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
How Strategic Real Estate Investments Are Driving Psychedelic Therapy's Growth, Bridging Gaps In Mental Healthcare
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
How Strategic Real Estate Investments Are Driving Psychedelic Therapy's Growth, Bridging Gaps In Mental Healthcare
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Rick Doblin Honored With Honey Badger Award For Fearless Psychedelic Advocacy At Psychedelic Science 2023
A Chapter In Psychedelics History: Alexander Shulgin's 'Blending' Of Sensory Experiences With Science And Chemistry

Rick Doblin Recent News

Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: How Are They Commercialized?
(Part four of a four-part series)
Michael Pollan's 'How To Change Your Mind' Coming Soon To Netflix: Documentary Based On Psychedelics Best Seller
The freshest news traversing many of the major institutions, researchers' and activists’ accounts on Twitter is the recent release of a docu-series based on writer Michael Pollan’s 2018 book “How To Change Your Mind: What the science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence.”
BREAKING: NFT Buyers, You Can Now Engage In Psychedelics' Legal Struggle At Christie's Auction To Support MAPS
Christie’s, the legendary art and luxury auction house, along with Dialectic and Vine Ventures, will auction off NFT works for those interested in digital art and supporting scientific studies.
Driver's Licenses To Trip On Psychedelics By 2035? Rick Doblin Maps Out The Future Of 'Spiritualized Humanity'
This article was originally published on Psychedelic Spotlight and appears here with permission.
Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
Wesana Health (CSE: WESA) (OTCQB: WSNAF) and the Multidisciplinary Association for Psychedelic Studies (MAPS) are teaming up to analyze the effectiveness of MDMA-assisted therapy in the treatment of traumatic brain injury (TBI).
Psyched: MindMed And Compass Q1 Earnings, FDA Approves Therapists Taking MDMA, Wesana Health Goes Public
Two of the most prominent companies in the psychedelics space released their financials for the first quarter of 2021.
Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY
These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments.
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed. 
Psyched: NeonMind, Novamind Go Public; MAPS And Field Trip Study MDMA, Psychedelics Center Launches In NYC
NeonMind Goes Public Psychedelics biotech company NeonMind debuted on the Canadian Securities Exchange (CSE) Monday under the symbol ‘NEON.’
'Psyched': MAPS Scores $30M, Mydecine Gets Psilocybin License, Psychedelic Science Sold
MAPS Gets $30M In Funds To Conclude MDMA Research
MAPS Completes $30M Fundraising, Heads Towards FDA Approval for MDMA
The Multidisciplinary Association for Psychedelic Studies, a non-profit working to legalize the psychedelic MDMA for assisted psychotherapy, announced Thursday that it has raised the $30 million necessary to complete phase 3 trials and achieve FDA approval for the drug.
MAPS And The Road To FDA Approval For MDMA
After 34 years of work, the Multidisciplinary Association for Psychedelic Studies (MAPS) is steps away from achieving FDA approval for MDMA-assisted psychotherapy in the treatment of post-traumatic stress disorder.  This would be the first time in history a psychedelic substance is approved by the U.S. Food and Drug Administration.